© Rosalind Scientific LLC 2018-2022
New Drug Hunter content, featured events and job postings straight to your inbox. Trusted by >4,000 drug hunters worldwide, unsubscribe anytime.
Home > ORN0829
<< Back to April
short T1/2 dual orexin 1/2 receptor antagonist
in clinical dev. for insomnia (Ph. II)
from ligand-based drug design
Bioorg. Med. Chem., Apr. 11, 2020
Taisho Pharmaceutical Co., Saitama, JP
ORN0829 is a dual inhibitor of orexins 1 and 2, designed to have a relatively short half life in humans for application in insomnia (to reduce side effects after waking…
Unlock this content with a Premium membership to read it now.